Aims: As the world population grows older, the co-existence of cancer and cardiovascular comorbidities becomes more common, complicating management of these patients. Here, we describe the impact of a large Cardio-Oncology unit in Southern Italy, characterizing different types of patients and discussing challenges in therapeutic management of cardiovascular complications. Methods and results: We enrolled 231 consecutive patients referred to our Cardio-Oncology unit from January 2015 to February 2020. Three different types were identified, according to their chemotherapeutic statuses at first visit. Type 1 included patients naïve for oncological treatments, Type 2 patients already being treated with oncological treatments, and Type 3 patients who had already completed cancer treatments. Type 2 patients presented the highest incidence of cardiovascular events (46.2% vs. 12.3% in Type 1 and 17.9% in Type 3) and withdrawals from oncological treatments (5.1% vs. none in Type 1) during the observation period. Type 2 patients presented significantly worse 48 month-survival (32.1% vs. 16.7% in Type 1 and 17.9% in Type 3), and this was more evident when in the three groups we focused on patients with uncontrolled cardiovascular risk factors or overt cardiovascular disease at the first cardiologic assessment. Nevertheless, these patients showed the greatest benefit from our cardiovascular assessments, as witnessed by a small, but significant improvement in ejection fraction during follow-up (Type 2b: from 50 [20; 67] to 55 [35; 65]; P = 0.04). Conclusions: Patients who start oncological protocols without an accurate baseline cardiovascular evaluation are at major risk of developing cardiac complications due to antineoplastic treatments.
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients / Cuomo, A.; Mercurio, V.; Varricchi, G.; Galdiero, M. R.; Rossi, F. W.; Carannante, A.; Arpino, G.; Formisano, L.; Bianco, R.; Carlomagno, C.; De Angelis, C.; Giuliano, M.; Matano, E.; Picardi, M.; Salvatore, D.; De Vita, F.; Martinelli, E.; Della Corte, C. M.; Morgillo, F.; Orditura, M.; Napolitano, S.; Troiani, T.; Tocchetti, C. G.. - In: ESC HEART FAILURE. - ISSN 2055-5822. - (2022). [10.1002/ehf2.13879]
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients
Cuomo A.;Mercurio V.;Varricchi G.;Galdiero M. R.;Rossi F. W.;Carannante A.;Arpino G.;Formisano L.;Bianco R.;Carlomagno C.;De Angelis C.;Giuliano M.;Matano E.;Picardi M.;Salvatore D.;Tocchetti C. G.
2022
Abstract
Aims: As the world population grows older, the co-existence of cancer and cardiovascular comorbidities becomes more common, complicating management of these patients. Here, we describe the impact of a large Cardio-Oncology unit in Southern Italy, characterizing different types of patients and discussing challenges in therapeutic management of cardiovascular complications. Methods and results: We enrolled 231 consecutive patients referred to our Cardio-Oncology unit from January 2015 to February 2020. Three different types were identified, according to their chemotherapeutic statuses at first visit. Type 1 included patients naïve for oncological treatments, Type 2 patients already being treated with oncological treatments, and Type 3 patients who had already completed cancer treatments. Type 2 patients presented the highest incidence of cardiovascular events (46.2% vs. 12.3% in Type 1 and 17.9% in Type 3) and withdrawals from oncological treatments (5.1% vs. none in Type 1) during the observation period. Type 2 patients presented significantly worse 48 month-survival (32.1% vs. 16.7% in Type 1 and 17.9% in Type 3), and this was more evident when in the three groups we focused on patients with uncontrolled cardiovascular risk factors or overt cardiovascular disease at the first cardiologic assessment. Nevertheless, these patients showed the greatest benefit from our cardiovascular assessments, as witnessed by a small, but significant improvement in ejection fraction during follow-up (Type 2b: from 50 [20; 67] to 55 [35; 65]; P = 0.04). Conclusions: Patients who start oncological protocols without an accurate baseline cardiovascular evaluation are at major risk of developing cardiac complications due to antineoplastic treatments.File | Dimensione | Formato | |
---|---|---|---|
ESC Heart Failure - 2022 - Cuomo - Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
4.66 MB
Formato
Adobe PDF
|
4.66 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.